StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a report released on Thursday morning. The brokerage issued a sell rating on the medical technology company’s stock.
BIOL has been the topic of a number of other reports. Benchmark reissued a speculative buy rating and set a $0.40 price objective on shares of BIOLASE in a report on Tuesday, May 14th. Maxim Group cut BIOLASE from a strong-buy rating to a hold rating in a report on Friday, May 24th.
View Our Latest Stock Analysis on BIOL
BIOLASE Stock Performance
BIOLASE (NASDAQ:BIOL – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. BIOLASE had a negative net margin of 43.56% and a negative return on equity of 1,782.73%. The firm had revenue of $11.56 million for the quarter.
Institutional Trading of BIOLASE
A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC increased its holdings in shares of BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the period. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is currently owned by hedge funds and other institutional investors.
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Stories
- Five stocks we like better than BIOLASE
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Stock Analyst Ratings and Canadian Analyst Ratings
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Stock Splits, Do They Really Impact Investors?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.